Cargando…

Therapeutic potential of a novel multifunctional iron chelator on cognitive decicits and insulin degrading enzyme expression in a rat model of sporadic Alzheimer's disease

Detalles Bibliográficos
Autores principales:	Knezović, Ana, Knapić, Marina, Osmanović-Barilar, Jelena, Mandel, Silvia, Youdim, Moussa, Riederer, Peter, Šalković-Petrišić, Melita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506331/ http://dx.doi.org/10.1186/2050-6511-13-S1-A65

Ejemplares similares

Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer’s Disease
por: Osmanovic Barilar, Jelena, et al.
Publicado: (2022)

Failure of the Brain Glucagon-Like Peptide-1-Mediated Control of Intestinal Redox Homeostasis in a Rat Model of Sporadic Alzheimer’s Disease
por: Homolak, Jan, et al.
Publicado: (2021)

The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
por: Osmanović Barilar, Jelena, et al.
Publicado: (2023)

Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease
por: Barilar, Jelena Osmanovic, et al.
Publicado: (2020)

From attention-deficit hyperactivity disorder to sporadic Alzheimer’s disease—Wnt/mTOR pathways hypothesis
por: Grünblatt, Edna, et al.
Publicado: (2023)

Nitrocellulose redox permanganometry: A simple method for reductive capacity assessment
por: Homolak, Jan, et al.
Publicado: (2021)

D-galactose might protect against ionizing radiation by stimulating oxidative metabolism and modulating redox homeostasis
por: Homolak, Jan, et al.
Publicado: (2023)

Exploratory Study of Gastrointestinal Redox Biomarkers in the Presymptomatic and Symptomatic Tg2576 Mouse Model of Familial Alzheimer’s Disease: Phenotypic Correlates and Effects of Chronic Oral d-Galactose
por: Homolak, Jan, et al.
Publicado: (2023)

Altered Secretion, Constitution, and Functional Properties of the Gastrointestinal Mucus in a Rat Model of Sporadic Alzheimer’s Disease
por: Homolak, Jan, et al.
Publicado: (2023)

The Effect of Acute Oral Galactose Administration on the Redox System of the Rat Small Intestine
por: Homolak, Jan, et al.
Publicado: (2021)

Association of Cognitive Deficit with Glutamate and Insulin Signaling in a Rat Model of Parkinson’s Disease
por: Knezovic, Ana, et al.
Publicado: (2023)

Repurposing a digital kitchen scale for neuroscience research: a complete hardware and software cookbook for PASTA
por: Virag, D., et al.
Publicado: (2021)

Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction
por: Grünblatt, Edna, et al.
Publicado: (2015)

Regional siderosis: a new challenge for iron chelation therapy
por: Cabantchik, Zvi Ioav, et al.
Publicado: (2013)

The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis and Aging
por: Kupershmidt, Lana, et al.
Publicado: (2023)

Physiological and pathological aspects of Aβ in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators
por: Avramovich-Tirosh, Yael, et al.
Publicado: (2008)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders?
por: Youdim, Moussa B. H.
Publicado: (2010)

A Novel Antioxidant Multitarget Iron Chelator M30 Protects Hepatocytes against Ethanol-Induced Injury
por: Xiao, Jia, et al.
Publicado: (2015)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
por: Youdim, Moussa B. H.
Publicado: (2010)

Oxidation-Induced Degradable Nanogels for Iron Chelation
por: Liu, Zhi, et al.
Publicado: (2016)

Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
por: Riederer, Peter, et al.
Publicado: (2023)

Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease
por: Riederer, P., et al.
Publicado: (2021)

Selegiline: a molecule with innovative potential
por: Tábi, Tamás, et al.
Publicado: (2019)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Iron Chelation in Local Infection
por: Scott, Cassidy, et al.
Publicado: (2021)

Role of Iron Chelators in Mucormycosis
por: Mahalmani, Vidya, et al.
Publicado: (2021)

Conservative Iron Chelation for Neuroferritinopathy
por: Marchand, Felix, et al.
Publicado: (2022)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Reversing oncogenic transformation with iron chelation
por: Abdelaal, Gina, et al.
Publicado: (2021)

Emerging Roles of the Iron Chelators in Inflammation
por: Di Paola, Alessandra, et al.
Publicado: (2022)

Role of microRNAs in the pathophysiology of sporadic colorectal cancer
por: Yong, Fung Lin, et al.
Publicado: (2012)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes
por: Mobarra, Naser, et al.
Publicado: (2016)

Chelators in the Treatment of Iron Accumulation in Parkinson's Disease
por: Mounsey, Ross B., et al.
Publicado: (2012)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

The Utility of Iron Chelators in the Management of Inflammatory Disorders
por: Lehmann, C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hrcuulajbahpup88si7e2sdaba